Gliomas in adults;Die gliome des erwachsenen

Deutsches Arzteblatt

Volumn 107, Issue 45, 2010, Pages 799-808

  Schneider, Thomas ^a   Mawrin, Christian ^a   Scherlach, Cordula ^a   Skalej, Martin ^a   Firsching, Raimund ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CARBAMAZEPINE; CILENGITIDE; CONTRAST MEDIUM; DEXAMETHASONE; ERLOTINIB; ETIRACETAM; GEFITINIB; IMATINIB; IRINOTECAN; ISOCITRATE DEHYDROGENASE; LAMOTRIGINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; TOPIRAMATE; TRANSFORMING GROWTH FACTOR BETA2; VALPROIC ACID;

ADULT DISEASE; ANAPLASTIC OLIGODENDROGLIOMA; ASTROCYTOMA; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSE ASTROCYTOMA; EPENDYMOMA; EPILEPSY; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; MEDICAL SOCIETY; MIXED GLIOMA; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PILOCYTIC ASTROCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; RECURRENT CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; ASTROCYTOMA; BRAIN; BRAIN NEOPLASMS; CELL MOVEMENT; CHILD; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 79851502267     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0799     Document Type: Review

References (25)

1. Zülch KJ: Brain Tumors. Their biology and pathology. Berlin-Heidelberg-New York: Springer Verlag, 1986.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO classfication of tumours of the central nervous system. Lyon, IARC 2007.
3. Wiestler OD: Pathologische Anatomie und WHO-Klassifikation der Tumoren des Nervensystems, in Schlegel U, Westphal M (eds.): Neuroonkologie. Stuttgart, New York: Georg Thieme Verlag, 1998: 4-46.
4. Uhlenbrock D, Forsting M: MRT und MRA des Kopfes. Stuttgart, New York: Georg Thieme Verlag, 2007.
5. Ricci PE, Dungan DH: Imaging of low- and intermediate-grade gliomas. Semin Radiat Oncol 2001; 11(2): 103-12. (Pubitemid 32275218)
6. Bell D, Chitnavis BP, Al Sarraj S, et al.: Pilocytic astrocytoma of the adult-clinical features, radiological features and management. Br J Neurosurg 2004; 18(6): 613-6. (Pubitemid 40101076)
7. Simon M, Schramm J: Surgical management of intracranial gliomas. Recent Results Cancer Res 2009; 171: 105-24.
8. van den Bent MJ, Afra D, De Witte O, et al.: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366(9490): 985-90. (Pubitemid 41323034)
9. Schramm J, Blumcke I, Ostertag CB, et al.: Low-grade gliomas - current concepts. Zentralbl Neurochir 2006; 67(2): 55-66. (Pubitemid 43672349)
10. Shaw E, Arusell R, Scheithauer B, et al.: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002; 20(9): 2267-76. (Pubitemid 34441653)
11. Wick W, Hartmann C, Engel C, et al.: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27(35): 5874-80.
12. Cairncross G, Berkey B, Shaw E, et al.: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24(18): 2707-14. (Pubitemid 46630566)
13. Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96. (Pubitemid 40349501)
14. Stummer W, Pichlmeier U, Meinel T, et al.: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5): 392-401.
15. Schlegel U, Westphal M: 2. Primäre Tumoren des Gehirns und seiner Häute: Gliome, in Schlegel U, Westphal M (eds.): Neuroonkologie. Stuttgart, New York: Thieme Verlag, 1998: 170-203.
16. Laperriere N, Zuraw L, Cairncross G: Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002; 64(3): 259-73. (Pubitemid 35254019)
17. Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10): 997-1003. (Pubitemid 40349502)
18. Wick W, Steinbach JP, Kuker WM, et al.: One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004; 62(11): 2113-5. (Pubitemid 38738235)
19. Böker DK, Winking M: Die Rolle von Boswellia-Säuren in der Therapie maligner Gliome. Dtsch Arztebl 1997; 94(18): A1197-9.
20. de Groot JF, Yung WK: Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008; 14(5): 279-85.
21. Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM: Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 2009; 29(12): 5171-84.
22. Hau P, Jachimczak P, Schlingensiepen R, et al.: Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007; 17(2): 201-12. (Pubitemid 47124417)
23. Weller M, Felsberg J, Hartmann C, et al.: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27(34): 5743-50.
24. Weller M, Stupp R, Reifenberger G, et al.: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010; 6(1): 39-51.
25. Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90(19): 1473-9. (Pubitemid 28482012)